AllianceBernstein
PMVP icon

AllianceBernstein’s PMV Pharmaceuticals PMVP Stock Holding History

AllianceBernstein’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,500
Closed -$85.8K – 3285
2024
Q1 		$85.8K Hold
50,500
– – ﹤0.01% 3039
2023
Q4 		$157K Sell
50,500
-2,970
-6% -$7.86K ﹤0.01% 3014
2023
Q3 		$328K Buy
53,470
+4,380
+9% +$30.1K ﹤0.01% 2775
2023
Q2 		$307K Buy
49,090
+2,590
+6% +$13.6K ﹤0.01% 2851
2023
Q1 		$222K Buy
46,500
+5,200
+13% +$36.6K ﹤0.01% 2876
2022
Q4 		$359K Hold
41,300
– – ﹤0.01% 2798
2022
Q3 		$491K Buy
41,300
+9,400
+29% +$136K ﹤0.01% 2662
2022
Q2 		$455K Buy
31,900
+15,400
+93% +$224K ﹤0.01% 2714
2022
Q1 		$344K Hold
16,500
– – ﹤0.01% 2831
2021
Q4 		$381K Buy
16,500
+3,300
+25% +$79.7K ﹤0.01% 2853
2021
Q3 		$393K Sell
13,200
-6,200
-32% -$198K ﹤0.01% 2851
2021
Q2 		$663K Buy
19,400
+9,600
+98% +$321K ﹤0.01% 2696
2021
Q1 		$322K Buy
9,800
+500
+5% +$19.7K ﹤0.01% 2869
2020
Q4 		$572K Buy
+9,300
New +$365K ﹤0.01% 2529

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

AllianceBernstein's PMVP Position: Q2 2024 in Review

AllianceBernstein sold out of PMV Pharmaceuticals (PMVP) in Q2 2024, closing a stake of 50,500 shares — an estimated $85.8K sold.

AllianceBernstein first reported a position in PMVP in Q4 2020 and held it in 14 quarters. The position peaked at $663K in Q2 2021. 93 funds tracked by Wall St. Rank hold PMVP as of Q2 2024.

  • AllianceBernstein reported no remaining PMV Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • AllianceBernstein sold 50,500 PMV Pharmaceuticals shares in Q2 2024, an estimated $85.8K.
  • AllianceBernstein first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • AllianceBernstein's PMV Pharmaceuticals position peaked at $663K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.